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MVEV was detected along the 
2011 through widespread seroc
chicken flocks after heavy rainf
High numbers of mosquitoes w
annulirostris predominating. In 2
numbers of cases of MVEV in
including nine cases (one death
four cases (one death) from th5) · 19 March 2012Murray Valley encephalitis virus (MVEV) is a mosquito-
borne virus that is found across Australia, Papua New 
Guinea and Irian Jaya.
MVEV is endemic to northern Australia and causes 
occasional outbreaks across south-eastern Australia.
2011 saw a dramatic increase in MVEV activity in endemic 
regions and the re-emergence of MVEV in south-eastern 
Australia.
This followed significant regional flooding and increased 
numbers of the main mosquito vector, Culex annulirostris, 
and was evident from the widespread seroconversion of 
sentinel chickens, fatalities among horses and several 
cases in humans, resulting in least three deaths.
The last major outbreak in Australia was in 1974, during 
which 58 cases were identified and the mortality rate was 
about 20%.
With the potential for a further outbreak of MVEV in the 
2011–2012 summer and following autumn, we highlight 
the importance of this disease, its clinical characteristics 
and radiological and laboratory features.
We present a suspected but unproven case of MVEV 
infection to illustrate some of the challenges in clinical 
management.
It remains difficult to establish an early diagnosis of 
MVEV infection, and there is a lack of proven therapeutic 
options.
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M ray Valley encephalitis virus (MVEV) is a mos-ito-borne virus. It is a member of the Japanesecephalitis serological complex of flaviviruses,
des Japanese encephalitis virus (JEV), West
Nile virus (WNV), Kunjin virus (KUNV), and others caus-
ing encephalitis worldwide. Major outbreaks of MVEV
occurred in Australia in 1951, 1956 and 1974, with the virus
first being isolated during the 1951 outbreak.1 MVEV may
have caused earlier outbreaks of Australian “X” disease in
1917–18, 1922 and 1925.2 In the most recent outbreak of
MVEV in 1974, 58 cases of encephalitis were identified,3
indicating the significance of this disease despite the
infrequency of epidemics.
MVEV is thought to be maintained in enzootic foci in
the north of Western Australia and the Top End of the
Northern Territory in a cycle involving waterbirds and
mosquitoes, primarily the species Culex annulirostris. Most
cases in humans since 1974 have occurred in these areas.
Activity outside the enzootic areas is believed to follow the
migration of infected waterbirds into flood-affected
areas.4,5 MVEV also infects a wide range of native and non-
native animals,6 but the role of these species in mainte-
nance and transmission of the virus is unclear. MVEV is
also endemic to Papua New Guinea and Irian Jaya.7
The sporadic nature of MVEV infection in south-eastern
Australia has led to the development of several models
attempting to predict epidemics. These include the
hypotheses of Forbes8 and Nicholls,9 which are based on
patterns of rainfall and other climatic conditions.3 The
predictive value of these models has been difficult to
ascertain because of the infrequency of MVEV activity in
south-eastern Australia, but it is likely that factors other
than just flooding are required for epidemics. Challenges
in prevention and control of MVEV also include difficulties
in controlling mosquito numbers during periods of exten-
sive flooding, and a lack of other prophylactic or treatment
measures for MVEV.
Recent circumstances
Murray River in February
onversion among sentinel
all and regional flooding.
ere also observed, with C.
011, there were increased
 humans across Australia,
) from Western Australia,
e Northern Territory, two
cases (one death) from South Australia, one case from New
South Wales, and one suspected but unproven case from
Victoria (see case history below).10 MVEV was also
detected in horses exhibiting neurological symptoms
across south-eastern Australia. Although the immediate
risk subsided with the onset of winter, it is important that
doctors consider MVEV infection in patients with a sugges-
tive clinical picture and who have been in regions of known
MVEV activity. In this review, we discuss current knowl-
edge of the clinical features of MVEV infection, challenges
in its diagnosis, and the limitations in treatment.
Report of a suspected case of Murray Valley 
encephalitis virus (MVEV) infection in Victoria
A 69-year-old man from the Murray River town of Mildura
presented to hospital in early March 2011 with a 3-day
history of agitation, a 1-day history of confusion, right-
sided weakness, ataxia, nausea and vomiting on a back-
ground of early Alzheimer dementia. A history of numer-
ous mosquito bites in the preceding weeks was elicited
from the family. Examination showed a mild right hemi-
paresis, ataxic gait and a Glasgow Coma Score (GCS) of
13/15 (verbal response, 4; eye opening, 4; motor response,
5). He was initially afebrile, and had a normal white cell
count and C-reactive protein level. A chest x-ray showed
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phy with contrast showed no acute abnormality. He was
treated with aspirin, ceftriaxone and azithromycin for a
presumed ischaemic stroke and pneumonia.
Over the ensuing 12 hours, the patient became febrile
(39C) and increasingly confused and agitated. He then had
a cardiac arrest, but was successfully cardioverted and
intubated. Cerebrospinal fluid (CSF) examination on Day 5
of symptoms showed a white cell count of 6  106/L (refer-
ence interval [RI], <5  106/L), an erythrocyte count of
7  106/L (RI, 0 106/L), a protein concentration of 1.11 g/L
(RI, 0.15–0.45 g/L) and a glucose concentration of 4.6mmol/
L (RI, 2.5–5.0 mmol/L); there was insufficient sample vol-
ume to measure the white cell differential. A gram stain and
bacterial culture were negative. Acyclovir and benzylpeni-
cillin were added to his antibiotic regimen to cover possible
herpes simplex virus (HSV) and Listeria monocytogenes
infection. The patient was then transferred to an intensive
care unit. Brain stem dysfunction was shown by a GCS of 3
(while not sedated), lack of spontaneous ventilation, blood
pressure instability, flaccid paralysis, occasional side-to-
side nystagmus, an absent gag and vestibulo-ocular
reflexes. An electroencephalogram showed diffuse slowing
consistent with encephalopathy. Therapy with dexametha-
sone was started, and the antibiotic cover broadened to
include meropenem and vancomycin.
Magnetic resonance imaging (MRI) of the brain on Day
9 of symptoms showed confluent high signal bilaterally in
the thalami, brainstem and the left precentral gyrus (Box
1). There was no evidence of ischaemic stroke, and find-
ings on magnetic resonance angiography were unremark-
able. Flavivirus-group and MVEV-specific reverse
transcription polymerase chain reaction (PCR) findings
were negative on CSF (Day 5, CSF diluted 1:2 because of
the small volume available), and on plasma (Day 8). PCRs
on CSF for alphavirus and herpes virus (types 1 and 2,
Epstein–Barr virus and cytomegalovirus) were also nega-
tive. Flavivirus IgG was detected in serum by immunofluo-
rescence (IF) on Day 4 at a titre of 1:640, but IF for flavivirus
IgM and an MVEV-specific epitope-blocking enzyme-
linked immunosorbent assay (ELISA) were negative. A
Day 8 serum sample tested at another reference laboratory
by epitope-blocking ELISA (targeting a different antigenic
region11) showed MVEV-specific antibodies at a titre of >1:
320, and was confirmed by a test for MVEV-specific neu-
tralising antibodies. The results of IF for MVEV IgM
remained negative. Other investigations did not show an
alternative diagnosis. Unfortunately, the patient showed
no clinical improvement and brain death was pronounced
on Day 10. Treatment was withdrawn and an autopsy
request was declined.
Clinical features
It is estimated that between 1 in 150 and 1 in 1000 MVEV
infections result in symptomatic disease.6,12 People of all
ages are affected and the clinical features comprise an
incubation period of 1–4 weeks (average, 2 weeks), then a
prodrome of 2–5 days that usually includes fever (often
> 40C) and headache.13-18 Other prodromal features may
include nausea, vomiting, diarrhoea, macular rash and
cough.15,17 Neurological features occur early and may
include lethargy, irritability and confusion. Seizures almost
invariably occur in children, and may also occur in adults.
Progression of neurological features varies, and four clini-
cal patterns have been described, including: relentless
progression to death; prominent spinal cord involvement
causing flaccid paralysis; cranial nerve/brainstem involve-
ment and tremor; and encephalitis followed by complete
recovery.17 Mild cases of encephalitis not requiring hospi-
talisation, and non-encephalitic cases with fever and head-
ache have also been described, suggesting a broad
spectrum of disease.15 The clinical presentations of infec-
tion with different encephalitic flaviviruses may overlap,
and clinical features cannot reliably differentiate between
these diseases. Nonetheless, JEV may be more likely to
cause Parkinsonian features, cranial nerve, cerebellar and
upper motor neuron signs,19 and WNV may cause flaccid
paralysis (suggesting an anterior horn cell process similar
to poliomyelitis), seizures, cerebellar ataxia, brachial plex-
opathy and optic neuritis.19 The case fatality rate of MVEV
is about 15%–30%,16,18 with long-term neurological
sequelae occurring in 30%–50% of survivors and only 40%
recovering completely.14-18 The pathogenic processes
mediating susceptibility to the disease are unknown, and it
remains unclear whether the higher incidence of disease
among Aboriginal people and males reflects exposure or a
specific pathogenic process.13-17 There are also no clearly
defined features that predict subsequent clinical outcomes,
although these appear to be worse in those with flaccid
paralysis, and in the young or the elderly.16,17
Radiological features
Radiological imaging makes a critical contribution to an
early diagnosis of MVEV infection, often providing sup-
portive information before serological results are available
and helping to exclude alternative diagnoses. MRI is the
most sensitive and specific type of imaging, and may show
positive findings within a week of symptom onset. Typical
features include bilateral hyperintensity of the deep grey
matter, especially the thalami, on fluid attenuation inver-
sion recovery or T2-weighted images (Box 1). These
changes may also involve the temporal lobes, red nucleus
and cervical spinal cord, and, in some cases, they may
resemble those seen in HSV encephalitis.20 Findings may
be similar for other flaviviruses, especially JEV and WNV,
1 Fluid attenuation inversion recovery magnetic resonance imagin
69-year-old man from flood-affected regional Victoria
Axial images (A and B) show diffuse high signal bilaterally in the thalami, cereb
midbrain (bold arrows). The coronal image (C) shows confluent high signal ch
the thalami to the midbrain and pons (bold arrows). The small hippocampi no
consistent with early Alzheimer disease (small arrows).2MJA 196 (5) · 19 March 2012
Clinical focus
MJA 196 (3
2 Recommended sa
Encephalitis virus
Sample
Early in the clinical co
Blood
Plasma (EDTA tub
Serum
CSF (at least 0.5 mL)
Throat swab or nasop
and faecal swabs
During convalescenc
(7–10 days later, and
Blood
Serum
CSF = cerebrospinal flui
PCR = polymerase chainand thus MRI does not allow discrimination between these
infections.20-24 Future studies are planned to determine if
MRI can be used to predict patient outcomes. Unfortu-
nately, MRI is not available in many rural areas and
computed tomography (CT), which is more widely availa-
ble, lacks the sensitivity to detect mild changes. In severe
disease, CT may detect hydrocephalus, reduced attenua-
tion from the thalami to the brainstem, cerebral atrophy or
cerebral infarcts.16,25
Laboratory tests
CSF findings in people with MVEV infection will usually
be consistent with a viral meningoencephalitis, comprising
a raised protein concentration, normal glucose concentra-
tion and a pleomorphic leukocytosis with a predominance
of mononuclear cells.14,16,17 However, data from other
flavivirus encephalitides such as WNV suggest that a
predominance of neutrophils may also occur.26 Laboratory
confirmation of a suspected MVEV infection requires
either the isolation of the virus itself, detection of MVEV
RNA, a fourfold rise in the IgG titre between acute and
convalescent serum samples, or detection of IgM in serum
or CSF (in the absence of cross-reactive antibodies).16,18,27
The precise duration of MVEV viraemia is uncertain, but,
for WNV viraemia, is less than 14 days from the time of
inoculation.28 Indeed, by the time neurological symptoms
develop, PCR testing of serum or CSF often returns a
negative result.20,29-32 The use of PCR in conjunction with
serological tests can increase the sensitivity of WNV diag-
nostic tests to 94% compared with 45% for serological tests
alone.33 Antigen detection assays are not available for
MVEV, but have been used for JEV and Dengue fever
virus.34,35
Serological tests remain the mainstay of confirmatory
diagnostic testing. Overseas experience with WNV and
JEV encephalitis suggests that IgM in serum usually
appears 4–9 days after disease onset and can persist for
months.16,28 This situation is thought to be similar for
MVEV but there are limited published data.29,37 Most
reference laboratories have developed in-house MVEV
serological tests that can detect total antibody by haemag-
glutination inhibition, IgG by immunofluorescence assays
(IFA) or enzyme immunoassays (EIA), and IgM by IFA or
EIA. However, cross-reactive antibodies remain problem-
atic, and may complicate the ability to distinguish between
MVEV and other flaviviruses.11 It is also possible that prior
immunisation with yellow fever virus or JEV vaccine may
induce cross-reactive antibodies.38 Neutralisation tests or
an epitope-blocking ELISA can help identify MVEV-spe-
cific antibodies.11,39 Recommended tests for suspected
MVEV are outlined in Box 2.
Treatment
Treatment of MVEV remains supportive, as there are no
therapeutic options of proven clinical value. Thus, early
transfer to a centre with intensive care facilities is essential.
Opportunities to assess potential treatments have been
limited because of low numbers of patients and the spo-
radic nature of cases distributed over a vast geographical
area. Experience with related flaviviruses, especially JEV
and WNV, have provided further insights, but clear treat-
ment options have not been identified for these infections
either.
Corticosteroids are potentially beneficial in reducing
intracranial pressure and modulating immune-mediated
pathology. They have been administered to patients with
MVEV, but have not been assessed in controlled studies.
Although glucocorticoids have been shown to increase
WNV viraemia in dogs,40 there is no evidence that they
worsen outcomes in humans. Dexamethasone was
assessed in a randomised control trial of 65 patients with
JEV and no benefit or detriment was observed.41 Therefore,
corticosteroids cannot be recommended for the definitive
treatment of flavivirus encephalitis, but may still be appro-
priate for the reduction of intracranial pressure.
No antiviral drugs have been trialled in the treatment of
humans with MVEV and there are few in-vitro or animal-
model data. There have also been few studies of antiviral
drugs for other flaviviruses. Ribavirin (already established
as therapy for hepatitis C virus, which is also in the
Flaviviridae family) was used in a study of 153 Indian
children with JEV encephalitis, but did not indicate any
benefit compared with placebo.42 Interferon alfa-2a has
also been assessed with a randomised, placebo-controlled
study in JEV encephalitis, and failed to show any benefit
compared with placebo in 112 Vietnamese children.43 The
role of antiviral drugs for JEV has recently been reviewed.44
The role of immunoglobulin therapy is also unclear. In
1917, a 12-year-old with features suggestive of MVEV
infection recovered after receiving immune serum.45 There
is also a report of a man with JEV recovering after being
administered non-immune intravenous immuno-
globulin.46 There are numerous reports of immunotherapy
for WNV encephalitis in Israel and the United States with
WNV-specific intravenous immunoglobulin (Omr-IgG-
am, Omrix Biopharmaceuticals, Tel Aviv, Israel) obtained
from donors with high titres of WNV antibodies. Results
have been variable, but a number of favourable outcomes
have been described.47,48 There is further evidence for the
benefit of intravenous immunoglobulin therapy in WNV
animal models, but only if administered early in the course
mples and tests for suspected infection with Murray Valley 
Test
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Clinical focusof the disease.49 Phase I/II clinical trials of WNV-specific
intravenous immunoglobulin therapy have recently been
completed in the US (NCT00069316), but results are yet to
be reported. Animal models of MVEV have shown that
IgG from humans and mice exposed to MVEV can protect
mice from symptomatic disease if they are transfused
before virus inoculation.50 The efficacy of intravenous
immunoglobulin therapy may not only be limited by
timing, but by penetration into the central nervous system
and its effect on intraneuronal virus.47
In light of these data, we cannot currently recommend
any specific antiviral therapy for infection with flavivirus
encephalitides, including MVEV, and the complex patho-
genesis of this disease means that there is a potential for
harm with some interventions (discussed below). There-
fore, we eagerly await further trial data on interventions
and the future development of effective antiviral agents.
Even with effective interventions, one of the challenges in
evaluating and using therapeutic agents against flavivirus
encephalitides is the early identification of cases and
initiation of treatment before significant neurological
impairment develops.
Prevention
There is currently no effective vaccination against MVEV
infection, and prevention relies on the use of sentinel
chicken flocks to provide a warning of virus activity, and
subsequent mosquito control. Interestingly, there are ani-
mal data indicating the potential importance of cross-
reactive responses in protection with a preclinical live
chimeric JEV vaccine (ChimeriVax-JE; Sanofi Pasteur, Lyon,
France) used to induce protection against JEV, MVEV and
WNV in mice.38 Such protective responses have not been
observed for currently available human vaccines for JEV or
yellow fever virus.38,50 The potential detriment of induced
responses must also be considered, whether induced by
immunisation or natural exposure. Indeed, there is evi-
dence from mouse studies of MVEV infection being
enhanced after vaccination with inactivated JEV vac-
cines.38,50 While an MVEV-specific vaccine is unlikely to be
developed commercially, because of the low burden of
disease and financial constraints, there may be a future role
for the use of a chimeric JEV vaccine to provide broad
protection against flavivirus infection, including MVEV.
However, further studies are needed.
Conclusions
The recent activity of MVEV across Australia decreased
with the arrival of winter, but the risk during this summer
and the coming autumn remains uncertain, especially in
areas that remain flooded. Recent circumstances remind us
of the limited information we have about this disease, the
challenges of clinical management, and the need to pre-
pare for future outbreaks. In addition to ongoing surveil-
lance of mosquitoes, virus activity, and the impact of public
health responses, further research is needed to improve
the capacity for early diagnosis, to identify effective treat-
ments and to improve preventive strategies.
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